Guangzhou clinical-stage biotech developing small-molecule cancer drugs, largely pre-revenue.
Guangzhou clinical-stage biotech developing small-molecule cancer drugs, largely pre-revenue.
In one line: A small, China-based oncology biotech.
Moat: none (IP / patents). Value depends on unproven clinical pipeline rather than an approved product.
Headquarters: Guangzhou, China · Employees: 160
Size BeBetter Med (688759.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $960M, the 2229th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.70 on 18 Nov 2026.
Performance Over six months the shares fell 57.8%, against -12.1% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥0 | CN¥0 | CN¥0 | CN¥0 | CN¥0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | CN¥0 | -CN¥13.7M | -CN¥13.4M | -CN¥10.5M | -CN¥4.94M |
| EBITDA | n/a | -CN¥164M | -CN¥150M | -CN¥184M | -CN¥221M |
| Net income | -CN¥291M | -CN¥154M | -CN¥56.0M | -CN¥173M | -CN¥188M |
| Free cash flow | -CN¥261M | -CN¥109M | -CN¥107M | -CN¥145M | -CN¥170M |
| Capital expenditure | CN¥61.7M | CN¥10.7M | CN¥18.9M | CN¥18.3M | CN¥42.3M |
| Total debt | CN¥3.12M | CN¥4.39M | CN¥5.84M | CN¥6.08M | CN¥8.41M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| BeBetter Med 688759.SS | $960M | -58% | n/a | n/a | n/a | n/a |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 8.0× | 13.4% |
| BeOne Medicines 688235.SS | $45.5B | +9% | +25% | 18% | 6.3× | 19.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688759.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.4% | -8.3% | 2nd lowest of 21 |
| 6-month return | -57.8% | -12.1% | lowest of 21 |
| Distance from 52-week high | -74.4% | -41.9% | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BeBetter Med 688759.SS | China | $960M | -58% | n/a | n/a | n/a | n/a | n/a |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $959M | -21% | -27% | -19% | 2.5× | n/a | n/a |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 2.2× | 2.3% | -0.5% |
| Nxera Pharma 4565.T | Japan | $974M | +46% | +24% | 14% | 5.4× | 17.7% | +27.3% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 2.0× | 17.6% | +7.8% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 3.8× | 11.6% | +4.9% |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 6.3× | 5.6% | +9.3% |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | 2.8× | 7.7% | -6.9% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | 1.8× | n/a | n/a |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 1.3× | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | 75.0× | 6.5% | -60.6% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | 4.7× | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | 4.5× | 10.3% | -13.7% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 1.4× | 2.3% | +1.8% |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | 6.5× | n/a | n/a |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 7.5× | -10.2% | +18.1% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 5.2× | 12.7% | +19.4% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 5.2× | 9.1% | +13.4% |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 4.2× | -2.0% | +18.7% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | 19.3× | n/a | n/a |